25999-04-6

Basic information

• Product Name: 4-Morpholinesulfonamide(8CI,9CI)
• Synonyms: 4-Morpholinesulfonamide(8CI,9CI);4-Morpholinesulfonamide
• CAS NO: 25999-04-6
• Molecular Formula: C₄H₁₀N₂O₃S
• Molecular Weight: 166.2
• Product Categories: SULFONAMIDE
• Mol File: 25999-04-6.mol
• Article Data: 20

Chemical Properties

• Melting Point: 160 °C
• Boiling Point: 331.4°Cat760mmHg
• Flash Point: 154.3°C
• Appearance: /
• Density: 1.46g/cm³
• Vapor Pressure: 0.000156mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 12.30±0.20(Predicted)
• CAS DataBase Reference: 4-Morpholinesulfonamide(8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Morpholinesulfonamide(8CI,9CI)(25999-04-6)
• EPA Substance Registry System: 4-Morpholinesulfonamide(8CI,9CI)(25999-04-6)

Safety Data

• Hazardous Substances Data: 25999-04-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C4H10N2O3S/c5-10(7,8)6-1-3-9-4-2-6/h1-4H2,(H2,5,7,8)

Upstream product

• 110-91-8 morpholine 
• 108555-00-6 4-nitrophenyl sulfamate 
• 861397-54-8 Boc-morpholine-4-sulfonic acid amide 
• 1048017-38-4 benzyl (morpholin-4-ylsulfonyl)carbamate 
• 1828-66-6 morpholine-4-sulfonyl chloride 
• 1189-71-5 isocyanate de chlorosulfonyle 

Downstream Products

• 20804-20-0 N-(morpholine-4-sulfonyl)-benzamidine 
• 92-53-5 4-Phenylmorpholine 
• 90470-88-5 Morpholine-4-sulfonic acid phenylamide 
• 115921-02-3 Morpholine-4-sulfonic acid (2-nitro-phenyl)-amide 
• 99168-83-9 N-(4-nitrophenyl)morpholine-4-sulfonamide 
• 60341-34-6 morpholine-4-sulfonic acid 1-diphenylphosphinoyl-ethylamide 
• 929632-38-2 2-bromo-3-cyclohexyl-N-[(4-morpholin-4-yl)sulfonyl]-1H-indole-6-carboxamide 
• 1025765-34-7 C₂₃H₂₃FN₄O₄S 
• 1127234-81-4 13-cyclohexyl-3-methoxy-6-(4-(4-morpholinylcarbonyl)-1,3-oxazol-5-yl)-N-(4-morpholinylsulfonyl)-7H-indolo[2,1-a][2]benzazepine-10-carboxamide 
• 1211973-90-8 4-methoxy-N-(morpholinosulfonyl)benzamide 
• 1211973-89-5 4-cyano-N-(morpholinosulfonyl)benzamide 

Relevant articles and documents

Diversely substituted sulfamides for fragment-based drug discovery of carbonic anhydrase inhibitors: synthesis and inhibitory profile

A series of sulfamide fragments has been synthesised and investigated for human carbonic anhydrase inhibition. One of the fragments showing greater selectivity for cancer-related isoforms hCA IX and XII was co-crystalized with hCA II showing significant potential for fragment periphery evolution via fragment growth and linking. These opportunities will be identified in the future via the screening of this fragment structure for co-operative carbonic anhydrase binding with other structurally diverse fragments.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independe